Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.
View all episodes
